Abstract:An siRNA screen targeting 96 deubiquitinases identifies USP52/PAN2 as crucial for xCT stability and ferroptosis in bladder cancer (BLCA). USP52 depletion impedes glutathione synthesis by promoting xCT degradation, increasing lipid peroxidation and ferroptosis, thereby suppressing BLCA progression. High USP52 levels correlate with aggressive disease and poor prognosis. In vivo, combining USP52 depletion with ferroptosis triggers IKE effectively restrains BLCA progression. Bladder cancer (BLCA) is a prevalent cancer with high case‐fatality rates and a substantial economic burden worldwide. Understanding its molecular underpinnings to guide clinical management is crucial. Ferroptosis, a recently described non‐apoptotic form of cell death, is initiated by the lethal accumulation of iron‐dependent lipid peroxidation products. Despite growing interest, the roles and vulnerabilities determining ferroptosis sensitivity in BLCA remain unclear. Re‐analysis of single‐cell RNA data reveals a decrease in high‐ferroptosis cancer cells as BLCA advances. USP52/PAN2 is identified as a key regulator of ferroptosis in BLCA through an unbiased siRNA screen targeting 96 deubiquitylases (DUBs). Functionally, USP52 depletion impedes glutathione (GSH) synthesis by promoting xCT protein degradation, increasing lipid peroxidation and ferroptosis susceptibility, thus suppressing BLCA progression. Mechanistically, USP52 interacts with xCT and enzymatically cleaves the K48‐conjugated ubiquitin chains at K4 and K12, enhancing its protein stability. Clinical BLCA samples demonstrate a positive correlation between USP52 and xCT expression, with high USP52 levels associated with aggressive disease progression and poor prognosis. In vivo, USP52 depletion combined with ferroptosis triggers imidazole ketone Erastin (IKE) synergistically restrains BLCA progression by inducing ferroptosis. These findings elucidate the role of the USP52‐xCT axis in BLCA and highlight the therapeutic potential of targeting USP52 and ferroptosis inducers in BLCA.

USP43 stabilizes c-Myc to promote glycolysis and metastasis in bladder cancer

Targeting MYC-enhanced Glycolysis for the Treatment of Small Cell Lung Cancer

Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression by Stabilizing c-MYC

USP29 coordinates MYC and HIF1α stabilization to promote tumor metabolism and progression

USP29 coordinates MYC and HIF1 stabilization to promote tumor metabolism and progression

Deubiquitylase USP52 Promotes Bladder Cancer Progression by Modulating Ferroptosis through Stabilizing SLC7A11/xCT

USP16 regulates castration-resistant prostate cancer cell proliferation by deubiquitinating and stablizing c-Myc

USP37 directly deubiquitinates and stabilizes c-Myc in lung cancer

USP21-mediated G3BP1 stabilization accelerates proliferation and metastasis of esophageal squamous cell carcinoma via activating Wnt/β-Catenin signaling

The role of deubiquitinase USP2 in driving bladder cancer progression by stabilizing EZH2 to epigenetically silence SOX1 expression

Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters

Suppression of Cancer Cell Stemness and Drug Resistance via MYC Destabilization by Deubiquitinase USP45 Inhibition with a Natural Small Molecule

Steroid Receptor Coactivator-3 Regulates Glucose Metabolism in Bladder Cancer Cells Through Coactivation of Hypoxia Inducible Factor 1Α

DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC

Phosphorylation of USP27X by PIM2 promotes glycolysis and breast cancer progression via deubiquitylation of MYC

USP24-GSDMB Complex Promotes Bladder Cancer Proliferation Via Activation of the STAT3 Pathway

The role of the HIF‐1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer

Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination

The KLF16/MYC feedback loop is a therapeutic target in bladder cancer

High Expression of SMYD3 Indicates Poor Survival Outcome and Promotes Tumour Progression Through an IGF-1R/AKT/E2F-1 Positive Feedback Loop in Bladder Cancer.

MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3